Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding

• Status: Completed
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Gastric variceal obturation is the current endoscopic therapy of choice for gastric variceal bleeding but is associated with a high rebleeding rate. Carvedilol is a potent non-selective β-blocker. The role of carvedilol in the prevention of recurrent gastric variceal bleeding is not studied. This study aimed at evaluating the efficacy of carvedilol as an adjunct to gastric variceal obturation in the secondary prophylaxis of gastric variceal bleeding.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Veterans General Hospital.
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• Age of 20 to 80 years

• Cirrhotic patients with acute gastric variceal bleeding proven by an endoscopy within 24 h of bleeding

• Stable hemodynamic condition for at least 3 days after cyanoacrylate injection

Exclusion Criteria:

• Previous treatment of gastric varices, including endoscopic therapy, transjugular intrahepatic porto-systemic shunt, or surgery

• Contraindications to non-selective beta-blockers or cyanoacrylate injection

• Serum total bilirubin >10 mg/dL

• Grade III/IV hepatic encephalopathy

• Hepato-renal syndrome

• Severe heart failure (NYHA Fc III/IV)

• Chronic kidney disease under renal replacement therapy

• Refractory ascites

• Malignancy other than hepatocellular carcinoma

• Pregnancy

• Pacemaker use

• Refusal to participate